Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Supernus Pharmaceuticals ( (SUPN) ) has shared an announcement.
On January 22, 2026, Supernus Pharmaceuticals, Inc. amended its September 12, 2018 merger agreement with Reich Consulting Group, Inc.’s securityholder representative, specifically revising the timing and payment of certain milestone obligations tied to that transaction. The change indicates Supernus is actively managing its merger-related financial commitments, which may affect the pacing of contingent payments to former stakeholders of the acquired business but does not alter the core terms of the underlying merger.
The most recent analyst rating on (SUPN) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Supernus Pharmaceuticals stock, see the SUPN Stock Forecast page.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Neutral.
Supernus Pharmaceuticals demonstrates strong product growth and a stable balance sheet, but faces profitability and cash flow challenges. The technical analysis suggests potential for recovery, while valuation metrics are currently unattractive. The earnings call provided a positive outlook, but highlighted operational losses and supply issues.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of prescription medicines, with growth initiatives that include strategic mergers and acquisitions structured with milestone-based payments.
Average Trading Volume: 816,561
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.82B
Find detailed analytics on SUPN stock on TipRanks’ Stock Analysis page.